Kenzel Sybille, Henneke Philipp
Zentrum für Kinderheilkunde und Jugendmedizin, Albert-Ludwigs Universität Freiburg, Freiburg, Germany.
Curr Opin Infect Dis. 2006 Jun;19(3):264-70. doi: 10.1097/01.qco.0000224821.27482.bd.
The advent of human Toll-like receptors has revolutionized our understanding of innate immunity. This review summarizes recent discoveries about the role of Toll-like receptors and innate immunity in neonatal sepsis with a particular emphasis on the paradigmatic organism S. agalactiae.
S. agalactiae stimulates phagocytes to excessive formation of inflammatory cytokines such as tumor necrosis factor, and Toll-like receptors are essential for this response both in vivo and in vitro. On the molecular level, distinct signaling pathways are engaged by released S. agalactiae toxins such as lipoteichoic acid (Toll-like receptor-2 dependent) and cell-bound toxins (Toll-like receptor-2 independent). In contrast, complement receptors and Fc receptors, but not Toll-like receptors, are directly involved in phagocytosis and therefore elimination of S. agalactiae. Notably, neonatal phagocytes potently activate cytokines in response to S. agalactiae but are deficient in S. agalactiae uptake and killing. Interference with the Toll-like receptor-dependent mitogen activated protein kinase cJun N-terminal Kinase improves outcome in a neonatal model of S. agalactiae sepsis by inhibiting cytokine formation but preserving clearance of S. agalactiae.
Recent progress in the understanding of S. agalactiae recognition and phagocytic signaling in neonatal sepsis suggests intermediates in the Toll-like receptor pathways as valuable targets for adjunctive sepsis therapy.
人类 Toll 样受体的出现彻底改变了我们对固有免疫的理解。本综述总结了关于 Toll 样受体和固有免疫在新生儿败血症中的作用的最新发现,特别强调了典型病原体无乳链球菌。
无乳链球菌刺激吞噬细胞过度形成炎性细胞因子,如肿瘤坏死因子,并且 Toll 样受体在体内和体外对这种反应都至关重要。在分子水平上,释放的无乳链球菌毒素,如脂磷壁酸(依赖 Toll 样受体 2)和细胞结合毒素(不依赖 Toll 样受体 2),会激活不同的信号通路。相比之下,补体受体和 Fc 受体而非 Toll 样受体直接参与吞噬作用,从而清除无乳链球菌。值得注意的是,新生儿吞噬细胞对无乳链球菌有强烈的细胞因子激活反应,但在摄取和杀灭无乳链球菌方面存在缺陷。干扰依赖 Toll 样受体的丝裂原活化蛋白激酶 cJun N 端激酶,通过抑制细胞因子形成但保留无乳链球菌清除能力,可改善无乳链球菌败血症新生儿模型的预后。
对新生儿败血症中无乳链球菌识别和吞噬信号传导的理解方面的最新进展表明,Toll 样受体途径中的中间体是辅助性败血症治疗的有价值靶点。